下颌下腺转位联合质子治疗保留唾液功能
本研究回顾17例接受根治性放疗的口咽癌患者,比较下颌下腺转位前后基于IMPT计划的对侧下颌下腺剂量。转位后重新优化使对侧下颌下腺平均剂量从32.92 Gy降至20.22 Gy,差异12.02 Gy(95%CI 9.46-14.59 Gy,p<0.001),靶区覆盖及其他危及器官剂量无显著差异。
要点
- 下颌下腺转位联合IMPT可显著降低对侧下颌下腺平均剂量。
- 转位后计划对侧下颌下腺平均剂量为20.22 Gy,较转位前降低12.02 Gy。
- 靶区覆盖、同侧下颌下腺及其他危及器官剂量无显著差异。
核心结论
- 下颌下腺转位可使IMPT计划中对侧下颌下腺获得更好的剂量保护。
研究设计与样本
- 回顾性分析17例接受根治性放疗并接受对侧下颌下腺转位的口咽癌患者,比较转位前与转位后IMPT计划的剂量学参数。
主要发现
- 转位前计划对侧下颌下腺平均剂量为32.92 Gy(范围17.82-47.6 Gy),转位后重新优化降至20.22 Gy(范围9.75-38.87 Gy),p<0.001。
- 转位后计划对侧下颌下腺平均剂量差异为12.02 Gy(95%CI 9.46-14.59 Gy;p<0.001)。
- 转位后计划更常满足对侧下颌下腺平均剂量约束。
- 靶区覆盖、同侧下颌下腺及其他危及器官剂量在两组计划间无显著差异。
关键数值与推荐
- 所有患者接受根治性放疗,剂量为66-70 Gy/30-35次。
临床怎么用
- 在IMPT时代,下颌下腺转位可作为进一步降低对侧下颌下腺剂量、减轻放射性口干的手段。
局限性
- 本研究为初步小样本回顾性研究,需更大样本的前瞻性研究支持临床转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Submandibular gland (SMG) transfer to the submental space in patients undergoing head and neck radiation therapy was historically performed to decrease radiation-associated xerostomia in the era of 2D/3D radiotherapy. In this study, we evaluated the dosimetric significance of SMG transfer with intensity modulated proton therapy (IMPT). METHODS: We reviewed patients with oropharyngeal carcinoma who received curative intent definitive radiation and had contralateral (C/L) SMG transfer. We registered the baseline diagnostic computed tomography (CT) scan of these patients with the CT simulation images and delineated pre-transfer and post-transfer SMG locations. IMPT pre-transfer plans were generated, taking into consideration the initial reference SMG position, and then re-optimized based on the post-transfer SMG position. Each patients' dosimetric parameters from both plans were compared for mean SMG doses, target coverage and other OAR doses. RESULTS: Seventeen patients were included in the analysis. All patients received definitive radiation (66-70 Gy/30-35 fractions). Pre-transfer plans had a C/L SMG mean dose of 32.92 Gy (range [R]: 17.82-47.6 Gy), which decreased to 20.22 Gy (R: 9.75-38.87 Gy), p < 0.001 on re-optimization. Post-transfer plans met the mean dose constraints more often than pre-transfer plans. The difference in C/L SMG mean dose with gland transfer was 12.02 Gy (95% CI: 9.46-14.59 Gy; p < 0.001). There was no significant difference in target coverage, ipsilateral SMG, and any other OARs between the plans. CONCLUSION: This pilot study demonstrates that SMG transfer enables better C/L SMG dose sparing during IMPT. Future prospective studies with larger patient cohorts are warranted to support clinical translation.
引用
- Yarlagadda S, Young GD, Rohe RM, et al. Integrating submandibular gland transfer with proton therapy to preserve salivary function. Clin Transl Radiat Oncol. 2026. PMID: 42676913. doi:10.1016/j.ctro.2026.101269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。